Hims & Hers Health and JetBlue Stock Analysis

Hims & Hers Health Stock Analysis

• 📉 Hims & Hers Health is experiencing its worst week ever, starting with a 35% crash due to a joint venture with Novo Nordisk.
• ⚠️ Novo Nordisk accused Hims & Hers of false advertising and endangering patients, leading them to pull out of the venture.
• 💡 Despite the setback, Hims & Hers has millions of users who prefer their discreet platform for sensitive health issues.
• 🚀 The stock might recover by focusing on distribution versus the original product manufacturer, as Hims & Hers can pivot to selling other versions of the medication.

JetBlue Stock Discussion

• ✈️ JetBlue's second-largest investor is reportedly considering selling its near 10% stake, according to Reuters.
• 📊 The stock's muted reaction to this news suggests it may already be significantly undervalued.
• 🔑 A portfolio manager shared wisdom on value traps, advising caution against prematurely deeming a stock a lost cause, as past poor performers can become top performers.
• 📈 JetBlue has new management in place since February 2024, and while they haven't had enough time to fully turn things around, there's potential for earnings growth and stock price improvement.
• 💰 The stock is considered cheap if it can return to $2 per share from its current low, with potential upside.
• 🚫 The discussion touches on the possibility of a reverse stock split to increase the stock price above $5, which might attract institutional investors.